Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 429,998
  • Shares Outstanding, K 92,672
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,380 K
  • EBIT $ -45 M
  • EBITDA $ -45 M
  • 60-Month Beta 1.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.38

Options Overview Details

View History
  • Implied Volatility 95.03% (-1.88%)
  • Historical Volatility 63.71%
  • IV Percentile 47%
  • IV Rank 7.68%
  • IV High 475.96% on 11/13/25
  • IV Low 63.34% on 05/27/25
  • Expected Move (DTE 9) 0.38 (8.23%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 217
  • Volume Avg (30-Day) 1,848
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 66,100
  • Open Int (30-Day) 61,373
  • Expected Range 4.27 to 5.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +46.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.78 +23.18%
on 02/12/26
5.18 -10.17%
on 03/04/26
+0.77 (+19.85%)
since 02/11/26
3-Month
3.49 +33.05%
on 01/02/26
5.36 -13.25%
on 01/22/26
+0.54 (+13.14%)
since 12/11/25
52-Week
2.86 +62.59%
on 11/14/25
13.99 -66.76%
on 07/24/25
-4.33 (-48.22%)
since 03/11/25

Most Recent Stories

More News
Anavex Life Sciences to Present at the Citizens Life Sciences Conference

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.65 (+0.22%)
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.65 (+0.22%)
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.65 (+0.22%)
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

AVXL : 4.65 (+0.22%)
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Company to host a  webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

AVXL : 4.65 (+0.22%)
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.65 (+0.22%)
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a...

AVXL : 4.65 (+0.22%)
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm

NEWTOWN, Pa. , Jan. 8, 2026 /PRNewswire/ -- Edelson Lechtzin LLP  is investigating potential violations of the federal securities laws involving Anavex Life Sciences Corp. ("Anavex") (NASDAQ:...

AVXL : 4.65 (+0.22%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are...

AVXL : 4.65 (+0.22%)
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.65 (+0.22%)

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

3rd Resistance Point 4.89
2nd Resistance Point 4.79
1st Resistance Point 4.72
Last Price 4.65
1st Support Level 4.55
2nd Support Level 4.45
3rd Support Level 4.38

See More

52-Week High 13.99
Fibonacci 61.8% 9.74
Fibonacci 50% 8.43
Fibonacci 38.2% 7.11
Last Price 4.65
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar